The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease-Reference-Cited by-同舟云学术

The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease

Published:2020-08-19 Issue:4 Volume:36 Page:893-909
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Chrysavgis Lampros¹^ORCID,Papatheodoridi Alkistis‐Maria¹,Chatzigeorgiou Antonios¹²,Cholongitas Evangelos³^ORCID

Affiliation:

1. Department of Physiology Medical School of National and Kapodistrian University of Athens Athens Greece

2. Institute for Clinical Chemistry and Laboratory Medicine University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden Dresden Germany

3. First Department of Internal Medicine Medical School of National and Kapodistrian University, General Hospital of Athens “Laiko” Athens Greece

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15202

Reference73 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

3. Non-alcoholic fatty liver disease: What the clinician needs to know

4. A population-based study on the prevalence of NASH using scores validated against liver histology

5. The burden of liver disease in Europe: A review of available epidemiological data

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

2. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials;Current Diabetes Reviews;2024-02

3. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts;Diabetes, Obesity and Metabolism;2024-01-17

4. Extraglycemic effects of NGLT2 inhibitors and effects on NAFLD as an effective way to improve cardiorenal prognosis in patients with type 2 diabetes;FOCUS. Endocrinology;2023-12-18

5. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD);Diabetes Obesity Metabolic Syndrome;2023-10-27